论文部分内容阅读
目的观察前列地尔用于急性心肌梗死PCI术后的临床效果。方法将急性心肌梗死行急诊冠脉介入(PCI)治疗患者120例随机分为前列地尔组与对照组各60例。2组患者均在入院后90min内给予PCI治疗。对照组患者术前给予拜阿司匹林300mg,氯吡格雷300mg嚼服,阿托伐给他钙40mg口服,术后给予低分子肝素钠6000U皮下注射。依据患者危险因素给予降低血压、防止心室重构,倍他乐克稳定心率等治疗。前列地尔组在对照组治疗基础上给予前列地尔10μg,每天2次,连续7d。治疗后采用心肌ECT检查心肌梗死面积,采用电化学发光法检测钠尿肽(BNP)水平,统计比较2组患者治疗后临床心电不良事件发生率。结果治疗后前列地尔组患者心肌梗死面积及钠尿肽水平明显低于对照组,临床不良心电事件发生率为31.67%(19/60)明显低于对照组的53.33%(32/60),差异均有统计学意义(P<0.05)。结论急性心肌梗死患者行PCI治疗后给予前列地尔治疗有助于患者心肌梗死面积减少,防治心脏功能恶化,减少术后不良临床心电事件发生。
Objective To observe the clinical effect of prostaglandin for acute myocardial infarction after PCI. Methods A total of 120 patients undergoing acute coronary intervention (PCI) with acute myocardial infarction were randomly divided into alprostadil group and control group, 60 cases each. Two groups of patients were given PCI within 90 minutes after admission. Patients in the control group were given aspirin 300mg, clopidogrel 300mg chewed clothes, atorvastatin 40mg orally, and low molecular weight heparin sodium subcutaneously after operation. Patients were given risk factors based on lower blood pressure, prevent ventricular remodeling, Betaloc stabilize heart rate and other treatment. The alprostadil group was given alprostadil 10μg twice daily for 7 days on the basis of the control group. Myocardial infarction size was measured by myocardial ECT after treatment. The level of natriuretic peptide (BNP) was detected by electrochemiluminescence. The incidence of clinical ECG adverse events in two groups were statistically compared. Results After treatment, the area of myocardial infarction and the level of natriuretic peptide in the patients in the alprostadil group were significantly lower than those in the control group (31.67%, 19/60), which were significantly lower than those in the control group (53.33%, 32/60) , The differences were statistically significant (P <0.05). Conclusions Alprostadil treatment in patients with acute myocardial infarction treated with alprostadil can reduce the area of myocardial infarction, prevent the deterioration of cardiac function and reduce the incidence of adverse clinical events.